We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is It Prudent to Add Teleflex Stock to Your Portfolio Now?
Read MoreHide Full Article
Key Takeaways
Teleflex's Vascular revenues rose 9% in Q2 2026, supported by central access and hemostatic demand.
Asia revenues jumped 59.5% to $76 million, driven mainly by $27.7 million in acquired revenues.
Tariffs and acquisition costs pressured margins, while pro forma net leverage improved to about 1.9X.
Teleflex’s (TFX - Free Report) Vascular business is well-positioned for growth in the upcoming quarters, led by sustained demand for central access and hemostatic products, coupled with new product introductions such as EZPLAZ. Further, the company’s expansion in Asia supports revenue growth. Strong solvency looks encouraging. Yet, a dull macro scenario remains a key concern for Teleflex.
Over the past year, this Zacks Rank #1 (Strong Buy) stock has fallen 1.9% against the industry’s 2.4% growth. The S&P 500 composite has risen 15.5% during the same period.
The global provider of medical technologies has a market capitalization of $5.52 billion. TFX’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 3.2%.
Let’s delve deeper.
Tailwinds for Teleflex
Vascular Business Grows: The Vascular portfolio continues to benefit from demand in central access and hemostatic products. In the second quarter of 2026, Vascular revenues rose 9% on a reported basis and 8% on a pro forma adjusted constant-currency basis. For the first six months of 2026, pro forma adjusted constant-currency growth was 6.4%, extending the positive trend from the first quarter. Product development also supports the longer-term case. In late July 2026, the FDA approved EZPLAZ Freeze Dried Plasma, the first freeze-dried plasma licensed by the agency, expanding Teleflex's emergency medicine offering within Vascular. Management characterized the underlying Vascular market as a mid-single-digit growth market, supporting a durable demand backdrop beyond near-term ordering patterns.
Business in Asia Holds Long-Term Potential: Teleflex continues to expand in Asia as the acquired Vascular Intervention business broadens its presence. In the second quarter of 2026, Asia net revenues increased 59.5% to $76.0 million, primarily from $27.7 million in acquired revenues. Asia operating profit rose 235.3% to $15.0 million despite higher operating and amortization expenses tied to the acquisition.
Balance-Sheet Flexibility Improves: Teleflex exited the second quarter of 2026 with cash and cash equivalents of $300.2 million. Current borrowings were $87.5 million, remaining well below the corresponding cash balance. Long-term borrowings were $2.72 billion at the second-quarter end. Following the OEM divestiture, pro forma net leverage declined to about 1.9X from 2.8X at quarter-end, as Teleflex used proceeds to repay the $700 million Term Loan A-2. The company continues to target about $800 million of debt reduction from strategic divestiture proceeds, which should strengthen balance-sheet flexibility and reduce interest expense.
Image Source: Zacks Investment Research
What Ails TFX?
Macroeconomic and Margin Risks: Teleflex remains exposed to tariffs, input costs and other global economic factors that can affect profitability. In the second quarter of 2026, adjusted gross margin declined 280 basis points (bps) year over year, primarily due to tariffs and the lower gross margin profile of the acquired Vascular Intervention business. Adjusted operating margin fell 520 basis points to 19.6% as gross margin erosion was compounded by higher operating expenses from the acquisition and increased R&D investment. The company also continues to face logistics, supplier and quality risks, although it managed through the lidocaine recall in the second quarter. If tariff costs persist or operating efficiencies take longer to emerge, margin recovery could remain gradual.
TFX Stock Estimate Trend
The Zacks Consensus Estimate for TFX’s 2026 earnings per share (EPS) has moved north by 1.8% to $7.22 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $2.28 billion, implying a 23.1% decline from the year-ago reported number.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Charles River Laboratories (CRL - Free Report) .
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, sporting a Zacks Rank of 1 at present, has an earnings yield of 6.7% against the industry’s negative 1.4% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 27.3% against the industry’s 3.8% decline over the past year.
Charles River, currently sporting a Zacks Rank of 1, has an estimated long-term earnings growth rate of 9.4% compared with the industry’s 13.2% growth. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.9%. CRL shares have gained 4% against the industry’s 3.8% decline over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Is It Prudent to Add Teleflex Stock to Your Portfolio Now?
Key Takeaways
Teleflex’s (TFX - Free Report) Vascular business is well-positioned for growth in the upcoming quarters, led by sustained demand for central access and hemostatic products, coupled with new product introductions such as EZPLAZ. Further, the company’s expansion in Asia supports revenue growth. Strong solvency looks encouraging. Yet, a dull macro scenario remains a key concern for Teleflex.
Over the past year, this Zacks Rank #1 (Strong Buy) stock has fallen 1.9% against the industry’s 2.4% growth. The S&P 500 composite has risen 15.5% during the same period.
The global provider of medical technologies has a market capitalization of $5.52 billion. TFX’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 3.2%.
Let’s delve deeper.
Tailwinds for Teleflex
Vascular Business Grows: The Vascular portfolio continues to benefit from demand in central access and hemostatic products. In the second quarter of 2026, Vascular revenues rose 9% on a reported basis and 8% on a pro forma adjusted constant-currency basis. For the first six months of 2026, pro forma adjusted constant-currency growth was 6.4%, extending the positive trend from the first quarter. Product development also supports the longer-term case. In late July 2026, the FDA approved EZPLAZ Freeze Dried Plasma, the first freeze-dried plasma licensed by the agency, expanding Teleflex's emergency medicine offering within Vascular. Management characterized the underlying Vascular market as a mid-single-digit growth market, supporting a durable demand backdrop beyond near-term ordering patterns.
Business in Asia Holds Long-Term Potential: Teleflex continues to expand in Asia as the acquired Vascular Intervention business broadens its presence. In the second quarter of 2026, Asia net revenues increased 59.5% to $76.0 million, primarily from $27.7 million in acquired revenues. Asia operating profit rose 235.3% to $15.0 million despite higher operating and amortization expenses tied to the acquisition.
Balance-Sheet Flexibility Improves: Teleflex exited the second quarter of 2026 with cash and cash equivalents of $300.2 million. Current borrowings were $87.5 million, remaining well below the corresponding cash balance. Long-term borrowings were $2.72 billion at the second-quarter end. Following the OEM divestiture, pro forma net leverage declined to about 1.9X from 2.8X at quarter-end, as Teleflex used proceeds to repay the $700 million Term Loan A-2. The company continues to target about $800 million of debt reduction from strategic divestiture proceeds, which should strengthen balance-sheet flexibility and reduce interest expense.
Image Source: Zacks Investment Research
What Ails TFX?
Macroeconomic and Margin Risks: Teleflex remains exposed to tariffs, input costs and other global economic factors that can affect profitability. In the second quarter of 2026, adjusted gross margin declined 280 basis points (bps) year over year, primarily due to tariffs and the lower gross margin profile of the acquired Vascular Intervention business. Adjusted operating margin fell 520 basis points to 19.6% as gross margin erosion was compounded by higher operating expenses from the acquisition and increased R&D investment. The company also continues to face logistics, supplier and quality risks, although it managed through the lidocaine recall in the second quarter. If tariff costs persist or operating efficiencies take longer to emerge, margin recovery could remain gradual.
TFX Stock Estimate Trend
The Zacks Consensus Estimate for TFX’s 2026 earnings per share (EPS) has moved north by 1.8% to $7.22 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $2.28 billion, implying a 23.1% decline from the year-ago reported number.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Charles River Laboratories (CRL - Free Report) .
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
VCYT sports a Zacks Rank of 1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Globus Medical, sporting a Zacks Rank of 1 at present, has an earnings yield of 6.7% against the industry’s negative 1.4% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 27.3% against the industry’s 3.8% decline over the past year.
Charles River, currently sporting a Zacks Rank of 1, has an estimated long-term earnings growth rate of 9.4% compared with the industry’s 13.2% growth. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.9%. CRL shares have gained 4% against the industry’s 3.8% decline over the past year.